Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CⅡTA-mediated up-regulation of MHC reverses immune evasion of leukemia stem cells in refractory/relapsed AML

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYuping SiBDBinbin Dai

Discussion

Loading...

Member takes

Overview

Experimental findings show enforced MHC expression enhances T-cell activity against leukemia stem cells, suggesting novel immunotherapy for AML.

Key Points

  • To investigate MHC expression effects on immune escape by leukemia stem cells and the potential of CIITA-mediated upregulation.
  • Isolated CD34+CD38- leukemia stem cells from KG-1a cell line using magnetic-activated cell sorting.
  • Conducted lentiviral transduction to express CIITA in LSCs for functional assays.
  • Evaluated MHC expression via qPCR and assessed T cell responses through co-culture and ELISA.
  • In vivo, engrafted humanized mice with altered LSCs and monitored tumor growth and immune responses.
  • CIITA overexpression increased HLA-B and HLA-C, elevating T cell responses including higher cytokine levels.
  • In vitro, co-culture with CIITA+ LSCs led to increased cytotoxicity and immune marker secretion compared to controls.
  • In vivo, tumors from CIITA+ LSCs exhibited more apoptosis but similar overall tumor volumes to controls.

Cite This Study

Si et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dcedhttps://doi.org/10.1182/blood-2025-1509
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 5552: MHC class II engager immunotherapy for the treatment of acute myeloid leukemia2026
  2. 2Leukemic stem cell–niche interaction through CLEC2-podoplanin axis confers drug resistance in acute myeloid leukemia2026
  3. 3Acute Myeloid Leukemia eradication targeting cathepsin g with a dual HLA-restricted TCR2025
  4. 4A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia2025
  5. 5The Acute Myeloid Leukemia microenvironment is defined by ineffective immune surveillance despite the presence of activated, clonally-expanded CD8 T cells with preserved effector function2025